David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Cheap Beyond Belief: FuelCell Energy Stock Has Ridiculous Upside Potential

By David Moadel, InvestorPlace Contributor

FuelCell Energy stock is down but definitely not out as FuelCell Energy strikes noteworthy deals in the U.S. and abroad.

More Than a Meme Stock? Chewy’s Strong Fundamentals and Buybacks Signal Upside Potential.

By David Moadel, InvestorPlace Contributor

Instead of buying Chewy stock with short-squeeze fantasies in mind, consider investing in Chewy because the company's sales are growing.

ADBE Analysis: Don’t Buy Adobe Stock Until It Falls to THIS Price

By David Moadel, InvestorPlace Contributor

Adobe stock will eventually reward patient investors as Adobe infuses its products with generative AI functionalities.

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

By David Moadel, InvestorPlace Contributor

Kazia Therapeutics stock is a fast mover in both directions and has long-term rally potential after Kazia Therapeutics' clinical victory.

Polestar Stock: This One Problem MUST Be Solved Before It’s Buyable

By David Moadel, InvestorPlace Contributor

Unless Polestar stock shoots higher and/or Polestar enacts a reverse share split, it will be tough to invest in the EV maker with confidence.

Load More